Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nutra Pharma has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, has renewed its collaborative agreement with the Centers for Disease Control and Prevention to study RPI-78M and RPI-MN as a possible therapy for rabies.
Subscribe to our email newsletter
RPI-78M is ReceptoPharm’s drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is its leading antiviral drug candidate.
Paul Reid, CEO of ReceptoPharm, said: “This collaboration with the Centers for Disease Control and Prevention (CDC) allows us to analyze various formulas for both RPI-78M and RPI-MN as possible treatments for rabies.
“Our goal with this study is to better understand the mechanism of action of our leading drug candidates and to determine their potential for treating advanced rabies infections.”